Rachel Abudu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rachel Abudu has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Kalina Duncan
US National Cancer Institute, Bethesda, MD
3 shared publicationsAnnette Boaz
Health and Social Care Workforce Research Unit, The Policy Institute, King’s College London , London WC2B 6NR
2 shared publicationsBilly Andre
Ali Chisti, Nour Sharara, Manaswi Gupta, Jane Craycroft, Ilyana Rosenberg, Billy Andre, Jennifer Silva, Ami Bhatt, and Franklin Huang, Global Oncology, Inc., United States; Camille Morgan, Kalina Duncan, Shannon Silkenson, and Ted Trimble, NCI Center for Global Health, United States; and Rachel Abudu, Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI at Frederick, Frederick, MD
2 shared publicationsCamille Morgan
Ali Chisti, Nour Sharara, Manaswi Gupta, Jane Craycroft, Ilyana Rosenberg, Billy Andre, Jennifer Silva, Ami Bhatt, and Franklin Huang, Global Oncology, Inc., United States; Camille Morgan, Kalina Duncan, Shannon Silkenson, and Ted Trimble, NCI Center for Global Health, United States; and Rachel Abudu, Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI at Frederick, Frederick, MD
2 shared publicationsIlyana Rosenberg
Ali Chisti, Nour Sharara, Manaswi Gupta, Jane Craycroft, Ilyana Rosenberg, Billy Andre, Jennifer Silva, Ami Bhatt, and Franklin Huang, Global Oncology, Inc., United States; Camille Morgan, Kalina Duncan, Shannon Silkenson, and Ted Trimble, NCI Center for Global Health, United States; and Rachel Abudu, Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI at Frederick, Frederick, MD
2 shared publicationsJane Craycroft
Ali Chisti, Nour Sharara, Manaswi Gupta, Jane Craycroft, Ilyana Rosenberg, Billy Andre, Jennifer Silva, Ami Bhatt, and Franklin Huang, Global Oncology, Inc., United States; Camille Morgan, Kalina Duncan, Shannon Silkenson, and Ted Trimble, NCI Center for Global Health, United States; and Rachel Abudu, Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI at Frederick, Frederick, MD
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Transforming Evidence
Optimising the value of clinical research to the UK
The UK has a long history of excellence in clinical research. Recently identified challenges to maintaining the quality and impact of clinical research include global systemic issues such as financial crises, ageing populations, and climate changes. Globally, clinical research has become a highly competitive arena as countries vie with one another for industry funding, rapid accruals of patients into trials, and growth and retention of qualified clinical research professionals (Benisheva et al., 2023). The UK’s clinical research is affected domestically by political and systemic issues like Brexit, NHS workforce recruitment and retention, growing health inequalities; and organisational factors such as research culture and resourcing within services. Well-documented issues like loss of NHS staff due to the Covid-19 pandemic, and increased regulatory burdens have contributed to a more complex clinical trials landscape within the UK (O’Shaughnessy, 2023, Deswal, 2023, Benisheva et al., 2023) and resulted in fewer patients having access to clinical trials (ABPI, 2022). Recruitment and development of new trials, particularly commercial trials, has waned since 2016. Yet, the Covid RECOVERY trial demonstrated the potential strength and global reach of UK clinical research (Hanney et al., 2022). Governments, funders, industry, academia and patients want to see the quality and impact of the UK’s clinical research improve. Our aim is to summarise the current state of UK clinical research funding, governance, and policy. Drawing together literature, interviews, and key policy reports, we summarise the facilitators and barriers of good clinical research in the UK and identify promising approaches which could be adopted by the UK to support improved clinical research practice, delivery and governance. In this report we: • map the current government structures and processes for clinical research within the UK Government and devolved administrations • provide an overview of the health services’ role in the delivery of UK clinical research • identify the wider political issues that might impact proposed policy improvements to the clinical research environment • identify the policy barriers and enablers to achieve a stronger research culture in the UK health service at a national, regional, and local level • consider the role played by other sectors, including industry, academia, and charities/foundations, and evaluate how effectively these sectors work together in the UK compared to other countries.
- 1 January 2025
- Published by Transforming Evidence
Open AccessOptimising the value of clinical research to the UK
The UK has a long history of excellence in clinical research. Recently identified challenges to maintaining the quality and impact of clinical research include global systemic issues such as financial crises, ageing populations, and climate changes. Globally, clinical research has become a highly competitive arena as countries vie with one another for industry funding, rapid accruals of patients into trials, and growth and retention of qualified clinical research professionals (Benisheva et al., 2023). The UK’s clinical research is affected domestically by political and systemic issues like Brexit, NHS workforce recruitment and retention, growing health inequalities; and organisational factors such as research culture and resourcing within services. Well-documented issues like loss of NHS staff due to the Covid-19 pandemic, and increased regulatory burdens have contributed to a more complex clinical trials landscape within the UK (O’Shaughnessy, 2023, Deswal, 2023, Benisheva et al., 2023) and resulted in fewer patients having access to clinical trials (ABPI, 2022). Recruitment and development of new trials, particularly commercial trials, has waned since 2016. Yet, the Covid RECOVERY trial demonstrated the potential strength and global reach of UK clinical research (Hanney et al., 2022). Governments, funders, industry, academia and patients want to see the quality and impact of the UK’s clinical research improve. Our aim is to summarise the current state of UK clinical research funding, governance, and policy. Drawing together literature, interviews, and key policy reports, we summarise the facilitators and barriers of good clinical research in the UK and identify promising approaches which could be adopted by the UK to support improved clinical research practice, delivery and governance. In this report we: • map the current government structures and processes for clinical research within the UK Government and devolved administrations • provide an overview of the health services’ role in the delivery of UK clinical research • identify the wider political issues that might impact proposed policy improvements to the clinical research environment • identify the policy barriers and enablers to achieve a stronger research culture in the UK health service at a national, regional, and local level • consider the role played by other sectors, including industry, academia, and charities/foundations, and evaluate how effectively these sectors work together in the UK compared to other countries.
- Open Access
- 22 July 2024
- Published by Oxford University Press (OUP) in Research Evaluation
- Vol. 33
Improving the reporting of research impact assessments: a systematic review of biomedical funder research impact assessments
The field of research impact assessment (RIA) has seen remarkable growth over the past three decades. Increasing numbers of RIA frameworks have been developed and applied by research funders and new technologies can capture some research impacts automatically. However, RIAs are too different to draw comparable conclusions about what type of methods, data or processes are best suited to assess research impacts of different kinds, or how funders should most efficiently implement RIAs. To usher in the next era of RIA and mature the field, future RIA methodologies should become more transparent, standardized and easily implementable. Key to these efforts is an improved understanding of how to practically implement and report on RIA at the funder-level. Our aim is to address this gap through two major contributions. First, we identify common items across existing best practice guidelines for RIA, creating a preliminary reporting checklist for standardized RIA reporting. Next, we systematically reviewed studies examining funders’ assessment of biomedical grant portfolios to examine how funders reported the results of their RIAs across the checklist, as well as the operational steps funders took to perform their RIA and the variation in how funders implemented the same RIA frameworks. We compare evidence on current RIA practices with the reporting checklist to identify good practice for RIA reporting, gaps in the evidence base for future research, and recommendations for future effective RIA.
- 22 July 2024
- Published by Oxford University Press (OUP) in Research Evaluation
- Vol. 33
Open AccessImproving the reporting of research impact assessments: a systematic review of biomedical funder research impact assessments
The field of research impact assessment (RIA) has seen remarkable growth over the past three decades. Increasing numbers of RIA frameworks have been developed and applied by research funders and new technologies can capture some research impacts automatically. However, RIAs are too different to draw comparable conclusions about what type of methods, data or processes are best suited to assess research impacts of different kinds, or how funders should most efficiently implement RIAs. To usher in the next era of RIA and mature the field, future RIA methodologies should become more transparent, standardized and easily implementable. Key to these efforts is an improved understanding of how to practically implement and report on RIA at the funder-level. Our aim is to address this gap through two major contributions. First, we identify common items across existing best practice guidelines for RIA, creating a preliminary reporting checklist for standardized RIA reporting. Next, we systematically reviewed studies examining funders’ assessment of biomedical grant portfolios to examine how funders reported the results of their RIAs across the checklist, as well as the operational steps funders took to perform their RIA and the variation in how funders implemented the same RIA frameworks. We compare evidence on current RIA practices with the reporting checklist to identify good practice for RIA reporting, gaps in the evidence base for future research, and recommendations for future effective RIA.
- Open Access
- 9 August 2022
- Published by Springer Nature in Health Research Policy and Systems
- Vol. 20 (1) , 1-18
What funders are doing to assess the impact of their investments in health and biomedical research
As pressures to maximize research funding grow, biomedical research funders are increasingly tasked with demonstrating the long-term and real-world impacts of their funded research investments. Over the past three decades, research impact assessments (RIA) have emerged as an important tool for analysing the impacts of research by incorporating logic models, frameworks and indicators to track measures of knowledge production, capacity-building, development of research products, adoption of research into clinical guidelines and policies, and the realization of health, economic and social benefits. While there are currently several models for RIA within the literature, less attention has been paid to how funders can practically select and implement a RIA model to demonstrate the impacts of their own research portfolios. In this paper, a literature review was performed to understand (1) which research funders have performed RIAs of their research portfolios to date; (2) how funders have designed their assessments, including the models and tools they have used; (3) what challenges to and facilitators of success have funders found when adopting the RIA model to their own portfolio; and (4) who participates in the assessments. Forty-four papers from both published and grey literature were found to meet the review criteria and were examined in detail. There is a growing culture of RIA among funders, and included papers spanned a diverse set of funders from 10 countries or regions. Over half of funders (59.1%) used a framework to conduct their assessment, and a variety of methods for collecting impact data were reported. Issues of methodological rigour were observed across studies in the review, and this was related to numerous challenges funders faced in designing timely RIAs with quality impact data. Over a third of articles (36.4%) included input from stakeholders, yet only one article reported surveying patients and members of the public as part of the assessment. To advance RIA among funders, we offer several recommendations for increasing the methodological rigour of RIAs and suggestions for future research, and call for a careful reflection of the voices needed in an impact assessment to ensure that RIAs are having a meaningful impact on patients and the public.
- 9 August 2022
- Published by Springer Nature in Health Research Policy and Systems
- Vol. 20 (1) , 1-18
Open AccessWhat funders are doing to assess the impact of their investments in health and biomedical research
As pressures to maximize research funding grow, biomedical research funders are increasingly tasked with demonstrating the long-term and real-world impacts of their funded research investments. Over the past three decades, research impact assessments (RIA) have emerged as an important tool for analysing the impacts of research by incorporating logic models, frameworks and indicators to track measures of knowledge production, capacity-building, development of research products, adoption of research into clinical guidelines and policies, and the realization of health, economic and social benefits. While there are currently several models for RIA within the literature, less attention has been paid to how funders can practically select and implement a RIA model to demonstrate the impacts of their own research portfolios. In this paper, a literature review was performed to understand (1) which research funders have performed RIAs of their research portfolios to date; (2) how funders have designed their assessments, including the models and tools they have used; (3) what challenges to and facilitators of success have funders found when adopting the RIA model to their own portfolio; and (4) who participates in the assessments. Forty-four papers from both published and grey literature were found to meet the review criteria and were examined in detail. There is a growing culture of RIA among funders, and included papers spanned a diverse set of funders from 10 countries or regions. Over half of funders (59.1%) used a framework to conduct their assessment, and a variety of methods for collecting impact data were reported. Issues of methodological rigour were observed across studies in the review, and this was related to numerous challenges funders faced in designing timely RIAs with quality impact data. Over a third of articles (36.4%) included input from stakeholders, yet only one article reported surveying patients and members of the public as part of the assessment. To advance RIA among funders, we offer several recommendations for increasing the methodological rigour of RIAs and suggestions for future research, and call for a careful reflection of the voices needed in an impact assessment to ensure that RIAs are having a meaningful impact on patients and the public.
- Open Access
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 602-610
Trends in International Cancer Research Investment 2006-2018
The International Cancer Research Partnership (ICRP) is an active network of cancer research funding organizations, sharing information about funded research projects in a common database. Data are publicly available to enable the cancer research community to find potential collaborators and avoid duplication. This study presents an aggregated analysis of projects funded by 120 partner organizations and institutes in 2006-2018, to highlight trends in cancer research funding. Overall, the partners’ funding for cancer research increased from $5.562 billion (bn) US dollars (USD) in 2006 to $8.511bn USD in 2018, an above-inflation increase in funding. Analysis by the main research focus of projects using Common Scientific Outline categories showed that Treatment was the largest investment category in 2018, followed by Early Detection, Diagnosis, and Prognosis; Cancer Biology; Etiology; Control, Survivorship, and Outcomes; and Prevention. Over the 13 years covered by this analysis, research funding into Treatment and Early Detection, Diagnosis, and Prognosis had increased in terms of absolute investment and as a proportion of the portfolio. Research funding in Cancer Biology and Etiology declined as a percentage of the portfolio, and funding for Prevention and Control, Survivorship and Outcomes remained static. In terms of cancer site–specific research, funding for breast cancer and colorectal cancer had increased in absolute terms but declined as a percentage of the portfolio. By contrast, investment for brain cancer, lung cancer, leukemia, melanoma, and pancreatic cancer increased both in absolute terms and as a percentage of the portfolio.
- 1 December 2021
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 7 (7) , 602-610
Open AccessTrends in International Cancer Research Investment 2006-2018
The International Cancer Research Partnership (ICRP) is an active network of cancer research funding organizations, sharing information about funded research projects in a common database. Data are publicly available to enable the cancer research community to find potential collaborators and avoid duplication. This study presents an aggregated analysis of projects funded by 120 partner organizations and institutes in 2006-2018, to highlight trends in cancer research funding. Overall, the partners’ funding for cancer research increased from $5.562 billion (bn) US dollars (USD) in 2006 to $8.511bn USD in 2018, an above-inflation increase in funding. Analysis by the main research focus of projects using Common Scientific Outline categories showed that Treatment was the largest investment category in 2018, followed by Early Detection, Diagnosis, and Prognosis; Cancer Biology; Etiology; Control, Survivorship, and Outcomes; and Prevention. Over the 13 years covered by this analysis, research funding into Treatment and Early Detection, Diagnosis, and Prognosis had increased in terms of absolute investment and as a proportion of the portfolio. Research funding in Cancer Biology and Etiology declined as a percentage of the portfolio, and funding for Prevention and Control, Survivorship and Outcomes remained static. In terms of cancer site–specific research, funding for breast cancer and colorectal cancer had increased in absolute terms but declined as a percentage of the portfolio. By contrast, investment for brain cancer, lung cancer, leukemia, melanoma, and pancreatic cancer increased both in absolute terms and as a percentage of the portfolio.
- 1 October 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Global Oncology
- Vol. 4 (Supplement) , 220s
A Snapshot of Global Oncology Programming at US Cancer Centers: Results of the 2018 US NCI/ASCO NCI-Designated Cancer Center Global Oncology Survey
Background: The US National Cancer Institute (NCI) Center for Global Health (CGH) serves as a clearinghouse of information on global oncology activities within the NCI and across the 70 NCI-designated Cancer Centers. Global oncology, as defined by the American Society of Clinical Oncology (ASCO), “addresses disparities and differences in cancer prevention, care, research, education and the disease's social and human impact around the world”. While CGH routinely reports on NCI-funded global oncology projects conducted at the cancer centers, there is limited reporting of non-NCI funded global oncology activities of the cancer centers. To address this gap, CGH has surveyed the cancer centers about their global oncology programs and projects informally in 2012 and 2014. The 2018 survey, in partnership with ASCO, represents the first systematically conducted survey, with new questions about cancer center global oncology programs, faculty, and trainees. Aim: The aim of the 2018 survey is to develop a summary report of cancer center global oncology programs for use by cancer centers as a knowledge sharing and collaborative tool; by the NCI to inform program development; and, by ASCO to better understand the current state of global oncology training at US institutions. Methods: CGH developed a 2-part online survey with questions about global oncology projects led by cancer centers, and the level of support for global oncology training and faculty engagement at cancer centers. CGH piloted the survey to 7 of the 70 cancer centers (10%) from January to March 2018. Revisions based on the pilot were made, and CGH fielded the survey to the rest of the 63 cancer centers (90%) from March to July 2018. CGH supplemented the survey data with an Internet search of cancer centers' Web sites. The submitted data will be compiled, analyzed, and organized into a summary report for distribution to NCI, ASCO, and the cancer centers. Results: Data from the 7 pilot institutions show that while all 7 institutions (100%) have a global oncology program, there is great variance in the percentage of global oncology faculty who receive external or administrative research grant support for their work. Three institutions (43%) report that 50% or fewer global oncology faculty receive external research grant support, and 6 institutions (86%) report that 50% or fewer global oncology faculty receive cancer center administrative fund support for their work. Additional results and analysis will be available and presented as part of this presentation. Conclusion: In addition to serving as a knowledge sharing and collaboration tool for cancer centers, the global oncology survey allows NCI, ASCO, and global oncology partners to understand the current landscape of and sources of support for global oncology training, research, and programming at the cancer centers. This information will inform future discussions on how to strengthen global oncology programming and partnerships.
- 1 October 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Global Oncology
- Vol. 4 (Supplement) , 220s
A Snapshot of Global Oncology Programming at US Cancer Centers: Results of the 2018 US NCI/ASCO NCI-Designated Cancer Center Global Oncology Survey
Background: The US National Cancer Institute (NCI) Center for Global Health (CGH) serves as a clearinghouse of information on global oncology activities within the NCI and across the 70 NCI-designated Cancer Centers. Global oncology, as defined by the American Society of Clinical Oncology (ASCO), “addresses disparities and differences in cancer prevention, care, research, education and the disease's social and human impact around the world”. While CGH routinely reports on NCI-funded global oncology projects conducted at the cancer centers, there is limited reporting of non-NCI funded global oncology activities of the cancer centers. To address this gap, CGH has surveyed the cancer centers about their global oncology programs and projects informally in 2012 and 2014. The 2018 survey, in partnership with ASCO, represents the first systematically conducted survey, with new questions about cancer center global oncology programs, faculty, and trainees. Aim: The aim of the 2018 survey is to develop a summary report of cancer center global oncology programs for use by cancer centers as a knowledge sharing and collaborative tool; by the NCI to inform program development; and, by ASCO to better understand the current state of global oncology training at US institutions. Methods: CGH developed a 2-part online survey with questions about global oncology projects led by cancer centers, and the level of support for global oncology training and faculty engagement at cancer centers. CGH piloted the survey to 7 of the 70 cancer centers (10%) from January to March 2018. Revisions based on the pilot were made, and CGH fielded the survey to the rest of the 63 cancer centers (90%) from March to July 2018. CGH supplemented the survey data with an Internet search of cancer centers' Web sites. The submitted data will be compiled, analyzed, and organized into a summary report for distribution to NCI, ASCO, and the cancer centers. Results: Data from the 7 pilot institutions show that while all 7 institutions (100%) have a global oncology program, there is great variance in the percentage of global oncology faculty who receive external or administrative research grant support for their work. Three institutions (43%) report that 50% or fewer global oncology faculty receive external research grant support, and 6 institutions (86%) report that 50% or fewer global oncology faculty receive cancer center administrative fund support for their work. Additional results and analysis will be available and presented as part of this presentation. Conclusion: In addition to serving as a knowledge sharing and collaboration tool for cancer centers, the global oncology survey allows NCI, ASCO, and global oncology partners to understand the current landscape of and sources of support for global oncology training, research, and programming at the cancer centers. This information will inform future discussions on how to strengthen global oncology programming and partnerships.
Ethical, Legal, and Social Implications of Personalized Genomic Medicine Research: Current Literature and Suggestions for the Future
Purpose: This review identifies the prominent topics in the literature pertaining to the ethical, legal, and social issues (ELSI) raised by research investigating personalized genomic medicine (PGM).Methods: The abstracts of 953 articles extracted from scholarly databases and published during a 5‐year period (2008–2012) were reviewed. A total of 299 articles met our research criteria and were organized thematically to assess the representation of ELSI issues for stakeholders, health specialties, journals, and empirical studies.Results: ELSI analyses were published in both scientific and ethics journals. Investigational research comprised 45% of the literature reviewed (135 articles) and the remaining 55% (164 articles) comprised normative analyses. Traditional ELSI concerns dominated the discourse including discussions about disclosure of research results. In fact, there was a dramatic increase in the number of articles focused on the disclosure of research results and incidental findings to research participants. Few papers focused on particular disorders, the use of racial categories in research, international communities, or special populations (e.g., adolescents, elderly patients, or ethnic groups).Conclusion: Considering that strategies in personalized medicine increasingly target individuals’ unique health conditions, environments, and ancestries, further analysis is needed on how ELSI scholarship can better serve the increasingly global, interdisciplinary, and diverse PGM research community.
Ethical, Legal, and Social Implications of Personalized Genomic Medicine Research: Current Literature and Suggestions for the Future
Purpose: This review identifies the prominent topics in the literature pertaining to the ethical, legal, and social issues (ELSI) raised by research investigating personalized genomic medicine (PGM).Methods: The abstracts of 953 articles extracted from scholarly databases and published during a 5‐year period (2008–2012) were reviewed. A total of 299 articles met our research criteria and were organized thematically to assess the representation of ELSI issues for stakeholders, health specialties, journals, and empirical studies.Results: ELSI analyses were published in both scientific and ethics journals. Investigational research comprised 45% of the literature reviewed (135 articles) and the remaining 55% (164 articles) comprised normative analyses. Traditional ELSI concerns dominated the discourse including discussions about disclosure of research results. In fact, there was a dramatic increase in the number of articles focused on the disclosure of research results and incidental findings to research participants. Few papers focused on particular disorders, the use of racial categories in research, international communities, or special populations (e.g., adolescents, elderly patients, or ethnic groups).Conclusion: Considering that strategies in personalized medicine increasingly target individuals’ unique health conditions, environments, and ancestries, further analysis is needed on how ELSI scholarship can better serve the increasingly global, interdisciplinary, and diverse PGM research community.
- Open Access
- 1 June 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Global Oncology
- Vol. 2 (3_suppl) , 9s-10s
A Global Cancer Project Map Integrating Global Cancer Statistics to Guide International Efforts
39 Background: In response to the growing burden of cancer, Global Oncology, Inc., and the National Cancer Institute Center for Global Health launched a free, online, interactive map, the Global Cancer Project Map (GCPM) [ http://gcpm.globalonc.org ], to allow policy makers, researchers, and civil society around the world to search this central repository of international cancer control and research projects. The GCPM serves to catalyze collaboration in cancer research and clinical care, as well as inform research and care gaps. Methods: In addition to search options by project attributes, the GCPM provides map overlays of epidemiological measures using IARC’s GLOBOCAN cancer-specific estimates of incidence, prevalence, and mortality, cancer disability--adjusted life years, and UN Human Development Index country values. Currently, the map displays projects with international collaborators collated from the NCI, NCI-Designated Cancer Centers, UICC and ASCO. Results: The GCPM search options offer countless angles of looking at projects worldwide. Of the 1,479 currently-mapped projects, 44.8% have investigators or collaborators in less-developed countries (LDCs) (as defined by the UN). Of the 1218 with a project type classification, 104 relate to capacity building and/or training, with 69 of these projects (66.3%) occurring in LDCs. Utilizing the cancer type search options, the GCPM currently displays 54 cervical cancer projects with LDC collaborators, where the cervical cancer mortality age--standardized risk is more than 2.5 times higher for LDCs than more-developed countries. Conclusions: The GCPM is a real-time needs assessment tool to allow the cancer community to visualize international efforts in cancer control and link need to action. To better address the growing burden of cancer, the partnership is actively seeking collaboration and additional project submissions. Utilized with cancer statistic overlays, the GCPM can help develop regional priorities in cancer research and control. Funding: This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: Ali Chisti No relationship to disclose Nour Sharara No relationship to disclose Manaswi Gupta No relationship to disclose Jane Craycroft No relationship to disclose Ilyana Rosenberg Employment: Connance, Inc., Hayes Management Consulting Camille Morgan No relationship to disclose Kalina Duncan No relationship to disclose Rachel Abudu No relationship to disclose Billy Andre No relationship to disclose Shannon Silkenson No relationship to disclose Jennifer Silva No relationship to disclose Ami Bhatt No relationship to disclose Ted Trimble No relationship to disclose Franklin Huang Stock or Other Ownership: GlaxoSmithKline, Abbvie
- 1 June 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Global Oncology
- Vol. 2 (3_suppl) , 9s-10s
Open AccessA Global Cancer Project Map Integrating Global Cancer Statistics to Guide International Efforts
39 Background: In response to the growing burden of cancer, Global Oncology, Inc., and the National Cancer Institute Center for Global Health launched a free, online, interactive map, the Global Cancer Project Map (GCPM) [ http://gcpm.globalonc.org ], to allow policy makers, researchers, and civil society around the world to search this central repository of international cancer control and research projects. The GCPM serves to catalyze collaboration in cancer research and clinical care, as well as inform research and care gaps. Methods: In addition to search options by project attributes, the GCPM provides map overlays of epidemiological measures using IARC’s GLOBOCAN cancer-specific estimates of incidence, prevalence, and mortality, cancer disability--adjusted life years, and UN Human Development Index country values. Currently, the map displays projects with international collaborators collated from the NCI, NCI-Designated Cancer Centers, UICC and ASCO. Results: The GCPM search options offer countless angles of looking at projects worldwide. Of the 1,479 currently-mapped projects, 44.8% have investigators or collaborators in less-developed countries (LDCs) (as defined by the UN). Of the 1218 with a project type classification, 104 relate to capacity building and/or training, with 69 of these projects (66.3%) occurring in LDCs. Utilizing the cancer type search options, the GCPM currently displays 54 cervical cancer projects with LDC collaborators, where the cervical cancer mortality age--standardized risk is more than 2.5 times higher for LDCs than more-developed countries. Conclusions: The GCPM is a real-time needs assessment tool to allow the cancer community to visualize international efforts in cancer control and link need to action. To better address the growing burden of cancer, the partnership is actively seeking collaboration and additional project submissions. Utilized with cancer statistic overlays, the GCPM can help develop regional priorities in cancer research and control. Funding: This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: Ali Chisti No relationship to disclose Nour Sharara No relationship to disclose Manaswi Gupta No relationship to disclose Jane Craycroft No relationship to disclose Ilyana Rosenberg Employment: Connance, Inc., Hayes Management Consulting Camille Morgan No relationship to disclose Kalina Duncan No relationship to disclose Rachel Abudu No relationship to disclose Billy Andre No relationship to disclose Shannon Silkenson No relationship to disclose Jennifer Silva No relationship to disclose Ami Bhatt No relationship to disclose Ted Trimble No relationship to disclose Franklin Huang Stock or Other Ownership: GlaxoSmithKline, Abbvie
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e18048
Mapping global cancer research and control in areas of low and middle income: The need for shared data on a single, interactive platform.
E18048 Background: In response to the growing global burden of cancer, Global Oncology, Inc., and NCI’s Center for Global Health propose a call to action to populate work in low- and middle-income areas onto an online platform to catalyze collaboration in cancer research and clinical care, while also informing research and care gaps. The platform, the Global Cancer Project Map (GCPM) [http://gcpm.globalonc.org], launched as a free, interactive map to fill this void. Methods: Currently, the GCPM displays projects with international collaborators collated from the NCI, NCI-Designated Cancer Centers, UICC and ASCO. In addition to search options by project attributes, the GCPM provides overlays of epidemiological measures using cancer-specific estimates of incidence, prevalence, and mortality, as well as disability-adjusted life-years, and Human Development Index country values. An online submission form is available for individuals and organizations working in this field to contribute, index their work, and build partnerships. Results: Of the 1479 currently-mapped projects, 44.8% have investigators or collaborators in less-developed countries (LDCs) (as defined by the UN by low gross national income, human asset index, and economic vulnerability index). Of the 1218 with a project type classification, 104 relate to capacity building and/or training, with 69 of these projects (66.3%) occurring in LDCs. Utilizing the cancer type search options, the GCPM currently displays 54 cervical cancer projects with LDC collaborators, where the cervical cancer mortality age-standardized risk is more than 2.5 times higher for LDCs than more-developed countries. Conclusions: The GCPM visualizes international efforts in cancer control and links need to action. To better address the growing burden of cancer, the partnership is actively seeking additional project submissions. Utilized with cancer statistic overlays, the GCPM can help develop regional priorities in cancer research and control.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e18048
Mapping global cancer research and control in areas of low and middle income: The need for shared data on a single, interactive platform.
E18048 Background: In response to the growing global burden of cancer, Global Oncology, Inc., and NCI’s Center for Global Health propose a call to action to populate work in low- and middle-income areas onto an online platform to catalyze collaboration in cancer research and clinical care, while also informing research and care gaps. The platform, the Global Cancer Project Map (GCPM) [http://gcpm.globalonc.org], launched as a free, interactive map to fill this void. Methods: Currently, the GCPM displays projects with international collaborators collated from the NCI, NCI-Designated Cancer Centers, UICC and ASCO. In addition to search options by project attributes, the GCPM provides overlays of epidemiological measures using cancer-specific estimates of incidence, prevalence, and mortality, as well as disability-adjusted life-years, and Human Development Index country values. An online submission form is available for individuals and organizations working in this field to contribute, index their work, and build partnerships. Results: Of the 1479 currently-mapped projects, 44.8% have investigators or collaborators in less-developed countries (LDCs) (as defined by the UN by low gross national income, human asset index, and economic vulnerability index). Of the 1218 with a project type classification, 104 relate to capacity building and/or training, with 69 of these projects (66.3%) occurring in LDCs. Utilizing the cancer type search options, the GCPM currently displays 54 cervical cancer projects with LDC collaborators, where the cervical cancer mortality age-standardized risk is more than 2.5 times higher for LDCs than more-developed countries. Conclusions: The GCPM visualizes international efforts in cancer control and links need to action. To better address the growing burden of cancer, the partnership is actively seeking additional project submissions. Utilized with cancer statistic overlays, the GCPM can help develop regional priorities in cancer research and control.